WuXi PharmaTech’s Suzhou Facility Passes FDA Inspection

WuXi PharmaTech has announced that its toxicology facility in Suzhou recently passed a surveillance Good Laboratory Practice (GLP) inspection by FDA with no major observations. This was the first FDA GLP inspection in the facility's five years of operation. The inspection was extensive, lasting five days and including the review of numerous processes and the audit of four studies. WuXi's toxicology facility in Suzhou has completed 92 IND-enabling programs for global submissions.

"The outcome of the FDA inspection further demonstrates the consistency of our GLP compliance and quality services following the excellent results of earlier OECD and CFDA inspections," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.

  • <<
  • >>